

1 **Age-Associated B cells predict impaired humoral immunity after COVID-19**
2 **vaccination in patients receiving immune checkpoint blockade**

3
4 Juan Carlos Yam-Puc^{1†*}, Zhaleh Hosseini^{1†}, Emily C. Horner^{1†}, Pehuén Pereyra
5 Gerber^{2,3†}, Nonantzin Beristain-Covarrubias^{1†}, Robert Hughes^{1†}, Maria Rust¹, Rebecca H.
6 Boston¹, Magda Ali¹, Edward Simmons-Rosello¹, Martin O'Reilly¹, Harry Robson¹, Lucy H.
7 Booth¹, Lakmini Kahanawita¹, Sofia Grigoriadou⁴, Andrea Correa-Noguera⁵, Lourdes Ceron-
8 Gutierrez⁵, Thomas Mulroney¹, Aleksei Lulla⁶, Katrin Fischer⁶, Andrew Craxton¹, Georgina
9 S.F. Anderson¹, Xiao-Ming Sun¹, Anne Elmer⁷, Caroline Saunders⁷, Areti Bermperi⁷, Sherly
10 Jose⁷, Mike Chapman¹, Marion MacFarlane¹, Anne E. Willis¹, Kiran R. Patil¹, Florian
11 Hollfelder⁶, Marko Hyvönen⁶, CITIID-NIHR COVID-19 BioResource Collaboration, Sarah
12 Spencer¹, Emily Staples¹, Matthew S. Buckland^{4,5}, Rainer Döffinger⁸, Christine Parkinson^{8§},
13 Sara Lear^{8§}, Nicholas J. Matheson^{2,3,8,9§}, James E. D. Thaventhiran^{1,2,8§*}.

14
15 ¹ Medical Research Council Toxicology Unit, School of Biological Sciences, University of
16 Cambridge, Cambridge, UK.

17 ² Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University
18 of Cambridge, UK

19 ³ Department of Medicine, University of Cambridge, Cambridge, UK

20 ⁴ Department of Clinical Immunology, Barts Health, London, UK.

21 ⁵ UCL GOSH Institute of Child Health Division of Infection and Immunity, Section of Cellular
22 and Molecular Immunology, London, UK.

23 ⁶ Department of Biochemistry, University of Cambridge, Cambridge, UK

24 ⁷ NIHR Cambridge Clinical Research Facility

25 ⁸ Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK

26 ⁹ NHS Blood and Transplant, Cambridge, UK

27
28 † These authors contributed equally

29 § These authors contributed equally

30 * Corresponding authors: jedt2@cam.ac.uk, jcy28@cam.ac.uk.

31
32 Key words: Inborn error of immunity (IEI), immune-checkpoint blockade, neutralising
33 antibodies, antigen-specific memory B cells, BNT162b2 vaccine, immunodeficiency, cancer

34
35 The authors declare no potential conflicts of interest.

37 **Abstract**

38 The effect of immune checkpoint blockade on COVID-19 immunity is unclear. In this study,
39 we determine whether immune checkpoint blockade expanded age-associated B cells
40 (ABCs) are similar to those present in other conditions, and whether they enhance or detract
41 from the COVID-19 vaccine responses. First, we use single cell RNA sequencing
42 (scRNAseq) to show that ABCs arising from distinct aetiologies have common transcriptional
43 profiles and may be further subdivided according to expression of genes associated with
44 different immune functions, including the autoimmune regulator (AIRE). Next, we perform
45 detailed longitudinal profiling of the COVID-19 vaccination response in patients. Finally, we
46 show that high pre-vaccination ABC frequency correlates with decreased levels of antigen-
47 specific memory B cells, and reduced magnitude and longevity of neutralising capacity
48 against authentic SARS-CoV-2 virus. Expansion of ABCs is a biomarker for individuals with
49 cancer requiring additional or more frequent booster immunisation against COVID-19.

50

51 **Introduction**

52 Despite the success of mRNA-lipid nanoparticle (mRNA-LNP) COVID-19 vaccines in
53 reducing the risk of symptomatic infection, hospitalisation, and death(1,2), vaccinated
54 patients with cancer remain at increased risk of severe outcomes following SARS-CoV-2
55 infection(3). A cancer therapy that observational studies(4-6) suggests could improve
56 vaccine efficacy is immune checkpoint blockade (ICB). By targeting PD-1 and CTLA-4
57 checkpoints, ICB non-specifically promotes T cell responses, including those involved in
58 anti-viral and anti-cancer immunity. Furthermore, preclinical evidence indicates immune
59 checkpoint blockade can, via T and B cell interactions, enhance antibody responses(7,8).
60 The neutralising antibodies produced by the humoral response are a vital component of
61 vaccine protection as they inhibit viral replication *in vitro* and correlate with protection against
62 infection *in vivo*(9-11). However, complicating the positive potential of ICB for vaccine
63 enhancement, ICB induces the expansion of a B cell subset termed in other contexts Age-
64 Associated B cells (ABCs)(12), which may have a confounding effect on humoral vaccine
65 responses.

66

67 ABCs comprise a naturally occurring population of antigen-experienced B cells which
68 expands continuously with age in healthy individuals but accumulates prematurely in people
69 with certain immune dyscrasias, autoimmunity, and/or infectious diseases(13). They have
70 also been termed CD11c⁺ B cells, CD11c⁺T-bet⁺ B cells, double negative 2 (DN2) B cells or
71 atypical memory B cells(13-17), and may additionally be generated by external
72 challenges(18,19), including COVID-19 infection and vaccination(20). Although ABCs are
73 associated with disease in autoimmunity, their role in vaccine immunity is uncertain. In mice,
74 these cells are required for optimal antibody responses following influenza vaccination(21),
75 possibly due to enhanced ability to present antigens to T cells relative to follicular B
76 cells(16,22). In patients with cancer treated with ICB, the expansion of ABCs precedes the
77 development of both antibody-mediated and non-antibody-mediated autoimmunity(12). This
78 is in keeping with their role in promoting antibody responses. However, we and others have
79 shown that expansion of ABCs is associated with antibody deficiency in specific cohorts of
80 patients with inborn errors of immunity (IEI)(23-26). These include patients with *NFKB1*
81 haploinsufficiency, in whom the genetic lesion leads predominantly to B cell-intrinsic
82 immunodeficiency(26), and patients with *CTLA4* haploinsufficiency, in whom the genetic-
83 lesion leads predominantly to a B cell-extrinsic functional T cell deficit (24,27). These
84 observations suggest two key questions: are the ABCs found in patients treated with ICB
85 equivalent to those found in other settings? And do these cells, when expanded through
86 distinct mechanisms, have a positive or negative effect on humoral vaccine responses?

87

88 The increase in patients with cancer eligible to receive ICB treatment(28) and the survival
89 benefit conferred by ICB treatment means that optimally protecting patients with cancer who
90 are receiving these therapies from infection will be an increasing priority. Here, we answer
91 the above questions regarding the characteristics and activity of ABCs in different patient
92 groups as well as developing an understanding of the crosstalk between ICB and successful
93 vaccination.

94

95 **Results**

96 **ABCs arising from distinct aetiologies have common transcriptional profiles**

97 We first assessed the similarities between ABCs from patients with different causes for ABC
98 expansion, using single cell RNA sequencing (scRNAseq). This included B cells from
99 healthy controls (HC, n=8), patients with cancer treated with ICB (ICB, n=8) and patients
100 with *NFKB1* or *CTLA4* haploinsufficiency (IEI, n=4), together with a published set of single B
101 cell transcriptomes from patients with SLE (n=3)(29). By focussing on patients with rare,
102 monogenic defects leading to well-characterised IEI, we were able to ensure that contrasting
103 B cell intrinsic (*NFKB1*) and extrinsic (*CTLA4*) aetiologies were included. Unsupervised
104 clustering of the 52,402 B cells, displayed in a uniform manifold approximation and
105 projection (UMAP) visualisation, revealed six clusters (**Fig. 1a-c**). Using CITE-seq, we
106 identified ABCs that had low CD21 and high CD11c surface protein expression, in keeping
107 with the definitions used in previous flow cytometry-based studies(12,26,30) (Supplementary
108 **Fig. 1a-b**). Cells were dispersed across all clusters regardless of the patient group or sex
109 from which they originated (**Fig. 1b-d**). ABC frequencies were higher in all patient groups
110 compared to healthy controls (**Fig. 1d**).

111

112 **Distinct subsets of ABCs express genes associated with distinct immune function**

113 The clustering and marker gene expression suggested that the ABC population can be
114 subdivided into “Classical ABCs”, “Anergic ABCs” and “CD1c ABCs” (**Fig. 1e**). Classical
115 ABC frequencies were higher in females and patients with SLE (**Fig. 1b-d** and
116 Supplementary **Fig. 1c-e**). ABCs have been described as “anergic B cells” (31,32),
117 interestingly, anergic ABCs (expressing canonical genes associated with anergy, such as
118 *EGR1* and *NR4A1*) clustered separately from Classical ABCs (**Fig. 1a and Fig. 1e** and
119 **Supplementary Table 1**), indicating heterogeneity within ABCs for this phenotype. Indeed,
120 many of the most differentially expressed genes in Classical ABCs were associated with
121 MHC class II-restricted antigen presentation (**Fig. 1f**). Gene ontology enrichment analysis
122 demonstrated selective upregulation of biological processes associated with professional

123 antigen presentation, such as antigen uptake, processing, class II presentation, and co-
124 stimulation (**Fig. 1g** and **Supplementary Table 2**). This was specific for MHC class-II-
125 restricted antigen presentation, as genes required for MHC class I-restricted antigen
126 presentation were instead differentially expressed in CD1c ABCs, relative to Classical ABCs
127 (Supplementary **Fig. 2**). This supports the functional separation of these two clusters, which
128 were less distinct on UMAP visualisation (**Fig. 1a**).

129

130 **Upregulation of AIRE and its target genes is seen in Classical ABCs**

131 We confirmed MHC-II antigen presentation related genes were amongst the most
132 differentially expressed genes of Classical ABCs (**Fig. 2a** and **Supplementary Table 3**).
133 Surprisingly, this analysis revealed the Autoimmune Regulator (AIRE) to be significantly
134 upregulated in Classical ABCs from all subject cohorts (**Fig. 2a-b**, Supplementary **Fig. 3**).
135 AIRE-expressing B lymphocytes were also in other clusters, albeit at a much lower
136 frequency (**Fig. 2c**). This is consistent with the accumulation of AIRE-expressing B cells in
137 the Classical ABC differentiation state during peripheral B cell development, rather than
138 selective upregulation of AIRE after ABC differentiation. Expression of a single gene in
139 3.85% of cells will make a negligible contribution to the UMAP clustering, therefore
140 enrichment of AIRE-expressing cells within the apex of the Classical ABC cluster
141 (Supplementary **Fig. 3a**) further supports the biological association of AIRE expression and
142 ABC differentiation. AIRE is a transcriptional regulator expressed in both the thymic
143 epithelium and thymic B cells(33,34), which increases expression of tissue-restricted
144 antigens (TRAs). TRA expression in the thymus is a central tolerance mechanism, whereby
145 stimulation of developing T cells by antigens usually expressed in non-thymic tissues directs
146 these cells away from fates with the potential for harmful self-antigen driven autoimmune
147 responses. Previous reports have suggested that AIRE is not functional in the small
148 proportion of peripheral lymphocytes in which it can be detected(35-37), although AIRE
149 function has never been assessed in ABCs (a peripheral B cell subset specifically
150 associated with autoimmune disease(16,38,39)). AIRE-expressing cells also upregulated a
151 set of genes previously defined as AIRE targets in thymic B cells(34) (**Fig. 2d** and
152 Supplementary **Fig. 3**). In addition, Classical ABCs upregulated HLA-G (Supplementary **Fig.**
153 **2**), a non-classical class I HLA molecule transactivated by AIRE in thymic epithelial cells(40).
154 Taken together, these data provide functional evidence of AIRE expression in Classical
155 ABCs. Further work will be necessary to evaluate if AIRE expression in ABCs leads to self-
156 antigen expression and productive presentation that can initiate autoimmune responses.

157

158 **ABC frequency predicts neutralising antibody response to COVID-19 vaccination**

159 To investigate the impact of ABCs on mRNA-LNP vaccination, we next analysed the
160 immune response to the mRNA BNT162b2 COVID-19 vaccine in patients with variable
161 expansion of ABCs, including healthy controls (HC, n=10), patients with cancer treated with
162 ICB (ICB, n=19) and patients with *NFKB1* or *CTLA4* haploinsufficiency (IEI, n=9) (**Fig. 3a**
163 and **Supplementary Table 4**). All subjects were invited for blood sampling prior to their
164 second vaccine dose (day 0), then at early (day 8), mid (day 21) and late (day 105) time
165 points after this dose (**Fig. 3a**). Classical ABC frequencies prior to vaccination (day 0) were
166 determined by multicolour flow cytometry staining for CD11c and CD21 (Supplementary **Fig.**
167 **4a**) and found to be elevated in patients compared with healthy controls (**Fig. 3b-c**).

168

169 Serum reactivity against SARS-CoV-2 spike (S), receptor-binding domain (RBD) and
170 nucleocapsid (NCP) antigens was evaluated at day 21 after the second dose in the
171 diagnostic immunology laboratory. The majority of patients (18/19 ICB, 5/8 IEI) generated
172 IgG antibodies against S and RBD antigens (encoded by BNT162b2) at levels similar to the
173 healthy control group (Supplementary **Fig. 4b**). These responses were unlikely to reflect
174 previous natural infection with SARS-CoV-2, as patients did not have evidence of NCP
175 reactivity (not encoded by BNT162b2) (Supplementary **Fig. 4b**). The quality of the COVID-
176 19-specific antibody response can be determined by measuring the capacity of serum to
177 neutralise authentic SARS-CoV-2 virus(41). Overall, most subjects displayed a rapid
178 increase in neutralising antibody titres, peaking early (day 8) after their second vaccine dose
179 (**Fig. 3d** and Supplementary **Fig. 4c**). By contrast, 5 patients (4 IEI and 1 ICB) failed to
180 develop detectable neutralising capacity at any time point, despite having detectable anti-S
181 antibodies. These patients are at greater risk of infection with SARS-CoV-2 and may be
182 susceptible to prolonged or refractory COVID-19(42,43).

183

184 Critically, the frequency of pre-vaccine ABCs was inversely correlated with neutralising
185 antibody titre at all timepoints (**Fig. 3e**), suggesting that ABCs predict both peak neutralising
186 capacity after vaccination, and the longevity of the neutralising antibody response. Indeed, at
187 day 105, 4/8 patients with IEI and 8/16 patients treated with ICB had neutralising antibody
188 titres which had fallen below the highest titre observed at day 0, compared with 0/7 HCs
189 (**Fig. 3d**). Individuals with neutralising capacity below this threshold showed higher
190 frequencies of ABCs than the individuals above it (**Fig. 3f**). Premature expansion of ABCs is
191 therefore seen both in patients with IEI and patients with cancer treated with ICB, and
192 (regardless of aetiology) correlates with a reduced ability to generate and maintain
193 neutralising antibody responses to COVID-19 vaccination.

194

195 **Premature expansion of ABCs is associated with lower levels of antigen-specific**
196 **memory B cells**

197 Whilst circulating antibodies derived from plasma cells wane over time, long-lived
198 immunological memory can persist in expanded clones of antigen-specific memory B cells.
199 We therefore assessed the frequency and differentiation of circulating SARS-CoV-2 RBD-
200 specific B cells elicited after the second dose of vaccine using multicolour flow cytometry
201 (Supplementary **Fig. 5a**). Strikingly, RBD-binding B cells were always significantly less
202 frequent in patients than in healthy controls (**Fig. 4a-b** and Supplementary **Fig. 5B**), and the
203 fraction of RBD-binding B cells amongst all CD19⁺ B cells correlated consistently with titres
204 of neutralising antibodies (Supplementary **Fig. 5c**). In addition, RBD-specific B cell
205 frequency immediately prior to the second vaccine dose correlated with neutralising capacity
206 at days 8 (peak response), 21 and 105 (**Fig. 4c**). This is consistent with a causal relationship
207 between the level of antigen-specific B cells prior to the second dose of vaccine, and the
208 magnitude and longevity of the neutralising antibody response. Furthermore, similar to
209 neutralising capacity, the levels of RBD-specific B cells at later timepoints could be predicted
210 by the frequency of ABCs at day 0 (**Fig. 4d**). Individuals with the highest frequencies of
211 ABCs showed reduced RBD-specific B cell differentiation (Supplementary **Fig. 5c-d**).

212
213 Finally, to analyse the cellular phenotype of rare RBD-binding B cells in a comprehensive,
214 unbiased way, we performed unsupervised clustering and UMAP visualisation of flow
215 cytometry data from all patients and HCs at all timepoints after vaccination (**Fig. 4e**). RBD-
216 binding B cells from both patients and HCs were observed within clusters of memory B cells
217 and plasmablasts (**Fig. 4f**), suggesting a quantitative reduction rather than qualitative
218 difference in the humoral response. Across all participants, the proportion of RBD-specific
219 cells expressing plasmablast markers peaked at day 8, whilst those expressing memory B
220 cell makers peaked a day 21 (**Fig. 4g**). Differentiation of antibody-producing cells therefore
221 occurs contemporaneously with peak neutralisation capacity (day 8). Since increased
222 antibody production cannot be driven by the proliferation of terminally differentiated (non-
223 dividing) plasma cells, a sizeable contribution to the neutralising antibody response after the
224 second dose of vaccine is likely the result of this memory B cell proliferation and
225 differentiation. Taken together, our data therefore suggest that premature expansion of
226 ABCs negatively impacts all aspects of the humoral immune response to COVID-19
227 vaccination.

228

229 **Discussion**

230 While the specific causal mechanism for ABC expansion in any single older patient (to which
231 polygenic risk alleles, ageing, therapy and obesity can all contribute) is unknown, in young
232 patients with ultra-rare monogenic inherited disease, expansion is caused by the specific
233 gene disrupted. Our analysis of 4 different patient groups: healthy controls, patients with
234 cancer treated with ICB, patients with autoimmune SLE, and patients with two distinct IEI
235 (CTLA haploinsufficiency and NFKB1 haploinsufficiency) demonstrates a homogeneity of the
236 ABC differentiation states irrespective of the specific cause. Therefore, the pathological
237 consequence of expanded ABCs is likely related to their increased frequency rather than an
238 inherent difference in these cells from patients with distinct diseases. Additionally, the finding
239 of AIRE and tissue restricted antigen expression within a small subset of Classical ABCs,
240 cells that transcriptionally appear as professional antigen presenting cells could provide a
241 mechanistic link between the expansion of these cells and the autoimmune toxicity
242 associated with ICB therapy.

243

244 Most clinically relevant, however, is our finding that patients with expanded ABCs have a
245 reduced B cell vaccine response, leading to reduced neutralisation capacity and reduced
246 memory B cell formation. Since memory B frequency before vaccination correlates with the
247 subsequent neutralisation response to immunisation, this predicts that there will be reduced
248 neutralisation capacity to subsequent booster immunisation. Consequently, patients with
249 expanded ABCs will require more frequent booster immunisation to achieve an equal level of
250 longitudinal B cell immune protection. Overall, these results place ABC frequency as a
251 predictive biomarker for reduced vaccine protection that could guide booster vaccination
252 schedules for patients at risk of breakthrough infection.

253

254 **Methods**

255 **Patient recruitment and ethics**

256 Enrolment of patients into this study was based on the deficiency of particular genes of
257 interest (IEI: CTLA4, LRBA, NFKB1, NFKB2) or clinical diagnostics (ICB, n = 19), whilst
258 healthy controls for this study were enrolled based on their clinical healthy status (n = 10).
259 Sample-size calculation was limited due to IEI patients in the study (n = 9) reflect a rare
260 population of individuals within the general population that we were able to recruit
261 (Supplementary Table 4).

262 The research was conducted in accordance with the principles of Good Clinical Practice and
263 following granted protocols of the National Institute for Health and Care Research (NIHR)
264 Bioresource of England or granted protocols of the Barts and the London Immunology
265 Registry, United Kingdom. Samples were collected with the written informed consent of all

266 study participants under the NIHR BioResource - Research Tissue Bank (NBR-RTB) ethics
267 (REC:17/EE/0025) or under the Barts and the London Immunology Registry (REC:
268 11/LO/1689), United Kingdom. Clinical data were collected by Clinical Immunology
269 Consultants at Cambridge University Hospital and Bart's Health at London, United Kingdom
270 via the Electronic Healthcare Record (Epic), or direct patient contact.

271 The patients and healthy controls were consented under the East of England Cambridge
272 South National research ethics committee (REC) reference 13/EE/0325 or Barts and the
273 London Immunology Registry (REC: 11/LO/1689), United Kingdom.

274

275 **Blood donation and separation**

276 Patients and controls gave voluntary blood samples prior to second dose and at early (day
277 8), mid (day 21) and late (day 105) timepoints following their second BNT162b2 vaccine.
278 Where sample size of individual assays was not the same as the total sample size, this was
279 because there was no sample collection at those specific time points. Samples may have
280 also been excluded if there was serological evidence of prior exposure to SARS-COV-2.
281 Peripheral blood samples were acquired in either lithium heparin or serum separating tubes.
282 Peripheral blood mononuclear cells (PBMCs) were isolated by a density gradient
283 centrifugation protocol and stored at -80°C for up to a week before being transferred to liquid
284 nitrogen until use. Whilst serum tubes were centrifuged to separate serum from cell pellet
285 before being aliquoted and stored at -80°C until use.

286

287 **Single cell library preparation and sequencing**

288 Frozen PBMCs were thawed and B cell population was enriched using magnetic separation
289 (Miltenyi 130-101-638). Samples were next labelled with oligonucleotide-tagged antibodies
290 against CD11c, CD21, CD27 and CD85j (TotalSeq, BioLegend). After labelled, cell counts
291 were adjusted to 1,035 cells per microlitre before being loaded onto a Chromium Next GEM
292 chip K (10X Genomics, 2000182) for the subsequent library's construction according to
293 Single cell 5' v2 protocol (CG000330 RevA, 10X Genomics). The library was quality
294 controlled by Agilent 4150 TapeStation and quantified by RT-PCR using the KAPA library
295 quantification kit for Illumina platforms (Roche, KK4824). Samples were sequenced on an
296 Illumina NovaSeq with a sequencing depth of at least 50, 000 reads per cell.

297

298 **Software versions**

299 Single cell data was analysed using Cell Ranger software version 6.1.1, citeseq version
300 1.5.0, R version 4.0.3 and R packages (Seurat 4.1.0, SeuratObject 4.0.4, Scuttle 1.0.4,
301 rstatix 0.7.0, tidyverse 1.3.0 and dplyr 1.0.8). Flow cytometry data and antibody titres were

302 analysed using FlowJo 10.7.1 and GraphPad Prism 9.1.2 (225), respectively. Figures were
303 produced using ggplot2 3.3.5, gridExtra 2.3, ComplexHeatmap 2.6.2, Nebulosa 1.0.2,
304 RColorBrewer 1.1-2, ggrepel 0.9.1, ggpubr 0.4.0, scales 1.1.1, showtext 0.9-5 in R and
305 GraphPad Prism 9.1.2 (225) and FlowJo 10.7.1.

306

307 **Preprocessing of scRNA-seq data**

308 Raw FASTQ files of the gene expression library were analysed using 10x Genomics Cell
309 Ranger software v.6.1.1[1] and aligned to the GRCh38 genome provided by Cell Ranger. All
310 Ig V, D, J and constant genes as well as TCR genes were deleted from the dataset so that
311 downstream analysis is not affected by highly variable clonotype genes. For the
312 quantification of antibody derived tags (ADT) and oligo hashtags, citeseq pipeline v.1.5.0[2]
313 was used. The generated hashtag count matrices as well as raw gene expression count
314 matrices were then used as inputs for the Seurat package v.4.1.0[3] in R v.4.0.3. Seurat
315 objects were created from the corresponding transcript count matrices. ADT assays were
316 added using CreateAssayObject function of Seurat to include expression levels of surface
317 proteins. Samples were then demultiplexed using HTODemux function. Doublets and cells
318 with no assigned hashtag were removed from objects for further analysis. Scuttle package
319 v.1.0.4[4] was used for quality control. 3 x Median absolute deviation (MAD) was considered
320 as the threshold for quality control; number of features and number of read counts were
321 filtered from both sides, whereas percentage of mitochondrial genes was filtered from upper
322 side. The samples were log-normalized for further differential expression analysis. Before
323 integrating all objects, they were normalized based on regularized negative binomial
324 regression using the SCTransform function of the Seurat package, regressing out for cell
325 cycle scores, number of counts and percentage of mitochondrial genes. The objects were
326 then integrated using the integration protocol of the Seurat package to perform batch effect
327 correction. The objects used for integration include: four groups of healthy controls each
328 having two subjects (total of 26900 cells in the final dataset), one group of IEI patients (5345
329 cells in the final dataset) and two groups of ICB patients (total of 9751 cells in the final
330 dataset) each having four subjects, and SLE patients with 3 subjects (10406 cells in the final
331 dataset).

332

333 **SLE data**

334 Data of SLE patients from Bhamidipati et al [5] was downloaded from GSE163121,
335 reprocessed and integrated with other objects using the same procedure as described
336 above.

337

338 **Clustering of data**

339 Principal component analysis (PCA) was performed on the integrated object to reduce the
340 dimensionality of the dataset. First, clustering was done using 30 principal components
341 (PCs) and resolution parameter of 0.1. Clusters with a high expression of non-B cell markers
342 were removed from the dataset. After deletion of all non-B cells, the dataset consists of
343 52402 cells. PCs were calculated in the new dataset and unsupervised clustering was
344 performed using 20 PCs and resolution parameter of 1.4. Cluster markers were calculated
345 with the default parameters of the FindMarkers function. Clusters with similar markers were
346 manually merged. Final clusters were labelled based on the differentially expressed genes in
347 each cluster.

348 Gene ontology enrichment analysis

349 Gene ontology [6, 7] enrichment analysis was performed via PANTHER [8] from
350 <http://www.geneontology.org> using the list of significantly upregulated genes from classical
351 ABC cluster (Average log₂ fold change > 0.25 and percent expressed in each group > 0.25).

352

353 **Geneset Scores**

354 A list of 74 Aire-induced genes were obtained from Yamano et al., [9] after converting mouse
355 gene IDs to human gene IDs. For calculating gene set score for each cell, AddModuleScore
356 function from Seurat package was used.

357

358 **Kernel density estimation of gene expression**

359 Nebulosa package v 1.0.2 [10] was used for calculating and plotting gene-weighted density
360 estimation of AIRE expression.

361

362 **SARS-CoV-2 serology**

363 A Luminex bead-based immunoassay was used to quantify specific antibodies to full-length
364 trimeric spike (S), spike receptor binding domain (RBD) and nucleocapsid (NCP) of SARS-
365 CoV-2 as previously described [11, 12]. Briefly, a multiplex assay was established by
366 covalently coupling recombinant SARS-CoV-2 proteins to distinct carboxylated bead sets
367 (Luminex, Netherlands). The S protein used here was the S-R/PP described in Xiong et al
368 [11], and the RBD protein was described by Stadlbauer et al [13]. The NCP protein used is a
369 truncated construct of the SARS-CoV-2 NCP protein comprising residues 48–365 (both
370 ordered domains with the native linker) with an N terminal uncleavable hexahistidine tag.
371 NCP was expressed in E. Coli using autoinducing media for 7h at 37°C and purified using
372 immobilised metal affinity chromatography (IMAC), size exclusion and heparin
373 chromatography. The S-, RBD- and NCP-coupled bead sets were incubated with patient

374 sera at 3 dilutions (1/100, 1/1000, 1/10000) for 1 h in 96-well filter plates (MultiScreen HTS;
375 Millipore) at room temperature in the dark on a horizontal shaker. After washes, beads were
376 incubated for 30 min with a PE-labeled anti-human IgG-Fc antibody (Leinco/Biotrend),
377 washed as described above, and resuspended in 100 μ l PBS/ Tween. Antibody-specific
378 binding was interpreted using Exponent Software V31 software on the Luminex analyzer
379 (Luminex / R&D Systems) and reported as mean fluorescence intensity (MFI). The
380 diagnostic thresholds used adhered to UK national guidelines.

381

382 **Neutralising antibodies to SARS-CoV-2**

383 The SARS-CoV-2 used in this study was a wildtype (lineage B) virus (SARS-CoV-
384 2/human/Liverpool/REMRQ0001/2020), a kind gift from Ian Goodfellow (University of
385 Cambridge), isolated early in the COVID-19 pandemic by Lance Turtle (University of
386 Liverpool) and David Matthews and Andrew Davidson (University of Bristol) [14-16] from a
387 patient on the Diamond Princess cruise ship. Sera were heat-inactivated at 56°C for 30 mins
388 before use, and neutralising antibody titres at 50% inhibition (NT50s) measured as
389 previously described [17, 18].

390 In brief, luminescent HEK293T-ACE2-30F-PLP2 reporter cells (clone B7) expressing SARS-
391 CoV-2 Papain-like protease-activatable circularly permuted firefly luciferase (FFluc) were
392 seeded in flat-bottomed 96-well plates. The next day, SARS-CoV-2 viral stock (MOI=0.01)
393 was pre-incubated with a 3-fold dilution series of each serum for 2 h at 37°C, then added to
394 the cells. 16 h post-infection, cells were lysed in Bright-Glo Luciferase Buffer (Promega)
395 diluted 1:1 with PBS and 1% NP-40, and FFluc activity measured by luminometry.
396 Experiments were conducted in duplicate.

397 To obtain NT50s, titration curves were plotted as FFluc vs log (serum dilution), then
398 analysed by non-linear regression using the Sigmoidal, 4PL, X is log(concentration) function
399 in GraphPad Prism. NT50s were reported when (1) at least 50% inhibition was observed at
400 the lowest serum dilution tested (1:20), and (2) a sigmoidal curve with a good fit was
401 generated. For purposes of visualisation and ranking, samples for which visual inspection of
402 the titration curve indicated inhibition at low dilutions, but which did not meet criteria (1) and
403 (2) above, were assigned an arbitrary NT50 of 4.

404 World Health Organisation International Standard 20/136 (WHO IS 20/136) has an NT50 of
405 1967 against wildtype SARS-CoV-2 when measured in this assay. This standard comprises
406 pooled convalescent plasma obtained from 11 individuals which, when reconstituted, is
407 assigned an arbitrary neutralising capacity of 1000 IU/ml against early 2020 SARS-CoV-2
408 isolates [19]. NT50s from this study may therefore be converted to IU/ml using a calibration

409 factor of 1000/1967 (0.51), with a limit of quantitation of 10.2 IU/ml (corresponding to an
410 NT50 of 20).

411

412 **Flow cytometric analysis of B cells**

413 Frozen PBMCs were thawed and stained with B cell panel antibody cocktail (Supplementary
414 Table 5). All samples were acquired on the BD LSRFortessa using FACSDIVA software
415 (BD-Biosciences). FCS files were exported and analysed using FlowJo v10.7.2 (BD-
416 Biosciences) software. Additionally, a uniform manifold approximation and projection
417 (UMAP) algorithm for dimensional reduction was performed on a concatenated FCS file
418 comprising events from the CD19+ gate from HC, IEI and ICB samples analysed, utilizing
419 the UMAP FlowJo plugin (v3.1). The composite samples were gated as indicated on
420 Supplementary Fig. 2 for RBD+ B cell identification and then overlaid by study group in the
421 UMAP generated, for additional visualisation. XShift (v1.4.1) and ClusterExplorer (1.5.15)
422 plugins were used for unsupervised cluster generation and exploration, respectively. Class-
423 switched memory B cells and plasmablasts/plasma cells were selected based on the
424 expression of CD19+IgD-IgM-CD38-CD27+ and CD19+IgD-IgM-CD38+/highCD27+/high,
425 respectively.

426

427 **RBD tetramer production**

428 SARS-CoV-2 RBD was expressed with N-terminal fusion of His-Zbasic-TEV module (8xHis
429 tag, Zbasic domain [20] and TEV protease cleavage site) and C-terminal Avi-tag in
430 BL21(DE3) cells (Novagen) cultured in 2xYT media at 37°C. RBD containing inclusion
431 bodies were isolated and solubilised. The denatured protein was first purified by immobilized
432 metal affinity chromatography using PureCube Ni-NTA resin, eluted and refolding was
433 allowed to proceed for 72 hours at 4°C. N-terminal fusion tag was cleaved off by NHis-
434 TEVpro (produced in-house). Biotinylation of the RBD protein was carried out using 5 mM
435 MgCl₂, 2 mM ATP, 150 μM biotin and 50 μg/ml of biotin ligase BirA-CHis (produced in-
436 house). The excess of biotinylated RBD protein was then incubated with 0.5 mg/ml of
437 fluorescently labelled Streptavidin (BioLegend) for 1 hour at room temperature and, finally,
438 RBD-Streptavidin complexes were separated by size exclusion chromatography using a
439 Superdex 200 Increase 10/300 GL column (Cytiva). The RBD-Streptavidin complexes were
440 then analysed by SDS-PAGE.

441

442 **Statistical analysis**

443 Statistical analysis for FACS and serology data was performed using GraphPad Prism
444 v9.1.1 (GraphPad Prism Software Inc). Two-tailed non-parametric Mann Whitney tests were

445 used to determine differences between groups. For multiple comparisons ANOVA with
446 Tukey's multiple comparisons test was used. Associations were calculated using two-tailed
447 Spearman's rank correlations and results are shown with linear trend levels. For the single
448 cell data, statistical significance for paired comparisons were performed using Wilcoxon rank
449 sum test in R.

450

451 **Data and code availability**

452 Sequencing data have been deposited in the Gene Expression Omnibus database [GEO: in
453 preparation]. Additional information and materials and all codes for scRNA-seq analysis will
454 be made available upon request.

455

456 **References**

457

- 458 1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, *et al.* Efficacy and
459 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **2021**;384(5):403-16
460 doi 10.1056/NEJMoa2035389.
- 461 2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, *et al.* Safety
462 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*
463 **2020**;383(27):2603-15 doi 10.1056/NEJMoa2034577.
- 464 3. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, *et al.*
465 COVID-19 vaccination and breakthrough infections in patients with cancer. *Ann*
466 *Oncol* **2022**;33(3):340-6 doi 10.1016/j.annonc.2021.12.006.
- 467 4. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I,
468 Alaguthurai T, *et al.* Safety and immunogenicity of one versus two doses of the
469 COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a
470 prospective observational study. *Lancet Oncol* **2021**;22(6):765-78 doi 10.1016/S1470-
471 2045(21)00213-8.
- 472 5. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A,
473 Shachor-Meyouhas Y, *et al.* Serologic Status and Toxic Effects of the SARS-CoV-2
474 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. *JAMA Oncol*
475 **2021**;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675.
- 476 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, *et al.*
477 Seroconversion rates following COVID-19 vaccination among patients with cancer.
478 *Cancer Cell* **2021**;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002.
- 479 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell
480 Positioning and Function. *Immunity* **2018**;49(2):264-74 e4 doi
481 10.1016/j.immuni.2018.06.012.
- 482 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, *et al.*
483 CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of
484 CD28 engagement. *Proc Natl Acad Sci U S A* **2015**;112(2):524-9 doi
485 10.1073/pnas.1414576112.
- 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, *et al.*
487 Neutralizing antibody levels are highly predictive of immune protection from
488 symptomatic SARS-CoV-2 infection. *Nat Med* **2021**;27(7):1205-11 doi
489 10.1038/s41591-021-01377-8.
- 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, *et al.* Infection and vaccine-
491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
492 *bioRxiv* **2021** doi 10.1101/2021.05.09.443299.
- 493 11. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, *et al.*
494 Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical
495 trial. *Science* **2022**;375(6576):43-50 doi 10.1126/science.abm3425.
- 496 12. Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, *et al.* Early B cell
497 changes predict autoimmunity following combination immune checkpoint blockade. *J*
498 *Clin Invest* **2018**;128(2):715-20 doi 10.1172/JCI96798.
- 499 13. Cancro MP. Age-Associated B Cells. *Annu Rev Immunol* **2020**;38:315-40 doi
500 10.1146/annurev-immunol-092419-031130.
- 501 14. Hao Y, O'Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely
502 responsive to innate stimuli accumulates in aged mice. *Blood* **2011**;118(5):1294-304
503 doi 10.1182/blood-2011-01-330530.

- 504 15. Kim CC, Baccarella AM, Bayat A, Pepper M, Fontana MF. FCRL5(+) Memory B
505 Cells Exhibit Robust Recall Responses. *Cell Rep* **2019**;27(5):1446-60 e4 doi
506 10.1016/j.celrep.2019.04.019.
- 507 16. Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, *et al.* Toll-
508 like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is
509 important for the development of autoimmunity. *Blood* **2011**;118(5):1305-15 doi
510 10.1182/blood-2011-01-331462.
- 511 17. Stewart A, Ng JC, Wallis G, Tsioligka V, Fraternali F, Dunn-Walters DK. Single-Cell
512 Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete
513 Development Pathways. *Front Immunol* **2021**;12:602539 doi
514 10.3389/fimmu.2021.602539.
- 515 18. Myles A, Sanz I, Cancro MP. T-bet(+) B cells: A common denominator in protective
516 and autoreactive antibody responses? *Curr Opin Immunol* **2019**;57:40-5 doi
517 10.1016/j.coi.2019.01.002.
- 518 19. Rubtsov AV, Marrack P, Rubtsova K. T-bet expressing B cells - Novel target for
519 autoimmune therapies? *Cell Immunol* **2017**;321:35-9 doi
520 10.1016/j.cellimm.2017.04.011.
- 521 20. Pape KA, Dileepan T, Kabage AJ, Kozysa D, Batres R, Evert C, *et al.* High-affinity
522 memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and
523 atypical memory B cells than those primed by mRNA vaccines. *Cell Rep*
524 **2021**;37(2):109823 doi 10.1016/j.celrep.2021.109823.
- 525 21. Johnson JL, Rosenthal RL, Knox JJ, Myles A, Naradikian MS, Madej J, *et al.* The
526 Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue
527 Distributions and Antibody Specificities in Mice and Humans. *Immunity*
528 **2020**;52(5):842-55 e6 doi 10.1016/j.immuni.2020.03.020.
- 529 22. Rubtsov AV, Rubtsova K, Kappler JW, Jacobelli J, Friedman RS, Marrack P. CD11c-
530 Expressing B Cells Are Located at the T Cell/B Cell Border in Spleen and Are Potent
531 APCs. *J Immunol* **2015**;195(1):71-9 doi 10.4049/jimmunol.1500055.
- 532 23. Gamez-Diaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, *et al.*
533 The extended phenotype of LPS-responsive beige-like anchor protein (LRBA)
534 deficiency. *J Allergy Clin Immunol* **2016**;137(1):223-30 doi
535 10.1016/j.jaci.2015.09.025.
- 536 24. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, *et al.* Immune
537 dysregulation in human subjects with heterozygous germline mutations in CTLA4.
538 *Science* **2014**;345(6204):1623-7 doi 10.1126/science.1255904.
- 539 25. Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, *et al.* Phenotype,
540 penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient
541 subjects. *J Allergy Clin Immunol* **2018**;142(6):1932-46 doi
542 10.1016/j.jaci.2018.02.055.
- 543 26. Tuijnburg P, Lango Allen H, Burns SO, Greene D, Jansen MH, Staples E, *et al.*
544 Loss-of-function nuclear factor kappaB subunit 1 (NFKB1) variants are the most
545 common monogenic cause of common variable immunodeficiency in Europeans. *J*
546 *Allergy Clin Immunol* **2018**;142(4):1285-96 doi 10.1016/j.jaci.2018.01.039.
- 547 27. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, *et al.* Autosomal
548 dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nat*
549 *Med* **2014**;20(12):1410-6 doi 10.1038/nm.3746.
- 550 28. Haslam A, Gill J, Prasad V. Estimation of the Percentage of US Patients With Cancer
551 Who Are Eligible for Immune Checkpoint Inhibitor Drugs. *JAMA Netw Open*
552 **2020**;3(3):e200423 doi 10.1001/jamanetworkopen.2020.0423.

- 553 29. Bhamidipati K, Silberstein JL, Chaichian Y, Baker MC, Lanz TV, Zia A, *et al.* CD52
554 Is Elevated on B cells of SLE Patients and Regulates B Cell Function. *Front Immunol*
555 **2020**;11:626820 doi 10.3389/fimmu.2020.626820.
- 556 30. Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, *et al.* Phenotype,
557 penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient
558 subjects. *J Allergy Clin Immunol* **2018** doi 10.1016/j.jaci.2018.02.055.
- 559 31. Isnardi I, Ng YS, Menard L, Meyers G, Saadoun D, Srdanovic I, *et al.* Complement
560 receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive
561 clones. *Blood* **2010**;115(24):5026-36 doi 10.1182/blood-2009-09-243071.
- 562 32. Terrier B, Joly F, Vazquez T, Benech P, Rosenzweig M, Carpentier W, *et al.*
563 Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in
564 hepatitis C virus infection-related autoimmunity. *J Immunol* **2011**;187(12):6550-63
565 doi 10.4049/jimmunol.1102022.
- 566 33. Gies V, Guffroy A, Danion F, Billaud P, Keime C, Fauny JD, *et al.* B cells
567 differentiate in human thymus and express AIRE. *J Allergy Clin Immunol*
568 **2017**;139(3):1049-52 e12 doi 10.1016/j.jaci.2016.09.044.
- 569 34. Yamano T, Nedjic J, Hinterberger M, Steinert M, Koser S, Pinto S, *et al.* Thymic B
570 Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction.
571 *Immunity* **2015**;42(6):1048-61 doi 10.1016/j.immuni.2015.05.013.
- 572 35. Hubert FX, Kinkel SA, Webster KE, Cannon P, Crewther PE, Proietto AI, *et al.* A
573 specific anti-Aire antibody reveals aire expression is restricted to medullary thymic
574 epithelial cells and not expressed in periphery. *J Immunol* **2008**;180(6):3824-32 doi
575 10.4049/jimmunol.180.6.3824.
- 576 36. Mathis D, Benoist C. Aire. *Annu Rev Immunol* **2009**;27:287-312 doi
577 10.1146/annurev.immunol.25.022106.141532.
- 578 37. Fergusson JR, Morgan MD, Bruchard M, Huitema L, Heesters BA, van Unen V, *et al.*
579 Maturing Human CD127+ CCR7+ PDL1+ Dendritic Cells Express AIRE in the
580 Absence of Tissue Restricted Antigens. *Front Immunol* **2018**;9:2902 doi
581 10.3389/fimmu.2018.02902.
- 582 38. Rubtsova K, Rubtsov AV, Thurman JM, Mennona JM, Kappler JW, Marrack P. B
583 cells expressing the transcription factor T-bet drive lupus-like autoimmunity. *J Clin*
584 *Invest* **2017**;127(4):1392-404 doi 10.1172/JCI91250.
- 585 39. Phalke S, Rivera-Correa J, Jenkins D, Flores Castro D, Giannopoulou E, Pernis AB.
586 Molecular mechanisms controlling age-associated B cells in autoimmunity. *Immunol*
587 *Rev* **2022**;307(1):79-100 doi 10.1111/imr.13068.
- 588 40. Melo-Lima BL, Poras I, Passos GA, Carosella ED, Donadi EA, Moreau P. The
589 Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic
590 epithelial cells. *Immunology* **2019**;158(2):121-35 doi 10.1111/imm.13099.
- 591 41. Gerber PP, Duncan LM, Greenwood EJ, Marelli S, Naamati A, Teixeira-Silva A, *et*
592 *al.* A protease-activatable luminescent biosensor and reporter cell line for authentic
593 SARS-CoV-2 infection. *PLoS Pathog* **2022**;18(2):e1010265 doi
594 10.1371/journal.ppat.1010265.
- 595 42. Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, *et al.*
596 Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an
597 Immunocompromised Patient. *J Infect Dis* **2021**;223(1):23-7 doi
598 10.1093/infdis/jiaa666.
- 599 43. Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, *et*
600 *al.* Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a
601 case report. *Nat Commun* **2020**;11(1):6385 doi 10.1038/s41467-020-19761-2.
- 602

603 **Figure Legends**

604

605 **Figure 1. Single cell transcriptional signature of ABCs.** Magnetically enriched B cells
606 from PBMCs were analysed through droplet-based single cell RNA sequencing technology
607 (n = 52402). **a-c.** UMAPs of cells from all individuals coloured by **(a)** annotated Louvain
608 clusters, **(b)** health condition (HC, healthy controls; ICB, immune-checkpoint blockade
609 treated cancer patients; IEI CTLA-4/NFKB1, inborn errors of immunity, CTLA-4 and NFKB1
610 mutants respectively; SLE, systemic lupus erythematosus patients), and **(c)** gender. Dots
611 represent a single cell. **d.** Proportion of total cells from each health condition belonging to
612 each cluster, clusters coloured as indicated. **e.** Expression of 46 genes in each B cell cluster
613 which define the different subpopulations. Dot size represents proportion of cells within a
614 cluster expressing the indicated gene and colours represent the average expression level. **f.**
615 Heatmap representing scaled expression values of genes associated with antigen uptake,
616 processing and class-II presentation in each cluster. **g.** Gene ontology enrichment analysis
617 of biological processes associated with upregulated genes in classical ABCs. GO terms with
618 highest fold enrichments are ranked by $-\log(P \text{ value})$. Dot size is proportional to the fold
619 enrichment.

620

621 **Figure 2. Classical ABC expression of AIRE and AIRE target genes.** **a.** Volcano plot
622 displaying the differentially expressed genes in ABCs compared to other B cell clusters.
623 Upregulated genes associated with antigen uptake, processing and MHC class II
624 presentation are labelled. AIRE gene is coloured in green. **b.** UMAP of all B cells coloured
625 by kernel density estimation of AIRE expression level across all identified B cell subsets.
626 UMAP showing the different B cell clusters inset. **c.** Percentage of cells which are AIRE⁺
627 in each cluster. **d.** Violin plot comparing expression score of tissue restricted antigens (gene
628 set from Yamano *et al*) in AIRE expressing cells and all other cells. Statistical testing via
629 Wilcoxon rank sum test.

630

631 **Figure 3. Correlation between frequency of ABCs and neutralising antibody response**
632 **to COVID-19 vaccination.** **a.** Cohort details. Samples were collected at days 0, 8, 21 and
633 105 after the 2nd dose of BNT162b2 vaccine (healthy controls (HC), grey; patients with rare
634 inborn errors of immunity (IEI): NFKB1 red, CTLA-4 and unclassified orange; patients
635 treated with ICB, blue). **b.** Representative FACS contour plots of CD21^{lo}CD11c⁺ ABCs in
636 CD19 B cells. **c.** Frequencies of B cells within total lymphocytes and frequencies ABCs
637 within total B cells, at day 0. **d.** Neutralising antibody titres at 50% inhibition (NT₅₀) against
638 wildtype SARS-CoV-2 at indicated timepoints after 2nd vaccine dose. The limit of detection of

639 the assay is indicated (grey dotted line at $NT_{50} = 20$), and an arbitrary threshold at the
640 highest NT_{50} from the HC group at day 0 (brown dashed line). **e.** Correlations between
641 frequencies of ABCs amongst B cells at day 0 and NT_{50} s at days 8, 21 and 105. **f.**
642 Frequencies of ABCs amongst $CD19^+$ B cells for individuals above and below the arbitrary
643 threshold indicated in panel **d** at day 105. Where specified, differences between groups
644 were determined using two-tailed non-parametric Mann Whitney tests. Spearman's rank
645 correlation coefficients (ρ) are shown, together with indicative linear regression lines plus,
646 **c-f** each point represents one individual.

647

648 **Figure 4. Correlation between frequency of RBD-specific B cells and neutralising**
649 **antibody response to COVID-19 vaccination.** **a.** Representative flow cytometry plots
650 displaying RBD-specific B cell populations amongst total $CD19^+$ B cells for different study
651 groups 0, 8, 21 and 105 days (D0, D8, D21 and D105) after the second dose of BNT162b2
652 vaccine. **b.** Frequencies of RBD-specific B cells amongst all $CD19^+$ B cells in HC, IEI and
653 ICB patients at days 0, 8, 21 and 105. Each dot represents a single individual (healthy
654 controls (HC), grey; patients with rare inborn errors of immunity (IEI): (NFKB1) red, (CTLA-4
655 and unclassified) orange; patients treated with ICB, blue). **c.** Correlations between
656 frequencies of RBD-specific B cells amongst all $CD19^+$ B cells at day 0 and NT_{50} s at days 8,
657 21 and 105. **d.** Correlations between frequencies of ABCs amongst B cells at day 0 and
658 frequencies of RBD-specific B cells at days 8, 21 and 105. **e.** UMAP projection of total B
659 cells from all donors at all time points displaying memory B cell (MBCs, purple) and
660 plasmablast (PBs, green) populations. **f.** RBD-specific B cells with MBC (purple) or PB
661 (green) phenotype are shown at days 0, 8, 21 and 105 (columns) for HC (top), IEI (middle)
662 and ICB (bottom) groups. **g.** Kinetics of RBD-binding cell frequencies amongst MBCs or
663 PBs. Samples with no detectable levels of RBD-specific cells are plotted at an arbitrary
664 value of 10^{-4} in (B) and 10^{-3} in (G). Where specified, statistical significance between groups
665 was determined using one-way ANOVA (G). P values for panel B are shown in
666 Supplementary Fig. 5. Spearman's rank correlation coefficients (ρ) are shown, together
667 with indicative linear regression lines where appropriate.

668

669 **Supplemental Figures and Tables**

670 **Supplementary Figure 1. Age-associated B cells converge transcriptionally amongst**
671 **individuals despite their disparate aetiology. a.** Magnetically enriched B cells from
672 PBMCs were labelled using barcode featuring and analysed through droplet-based single
673 cell RNA sequencing technology. Expression of surface protein CD11c against CD21 in all B
674 cells. **b.** Violin plots of CD21 and CD11c surface protein expression in ABCs versus other B
675 cells with CLR-normalised expression values. Statistical testing via Wilcoxon rank sum test
676 with Bonferroni correction. **c.** UMAPs of total B cells per health condition coloured by
677 annotated clusters (HC, healthy controls; ICB, immune-checkpoint blockade treated patients;
678 IEI CTLA-4/NFKB1, immune errors of immunity, CTLA-4 and NFKB1 mutants respectively;
679 SLE, systemic lupus erythematosus patients). **d.** Number of samples from each gender,
680 coloured as indicated, in each health condition group. **e.** Clusters, with percentages of cells
681 from each gender coloured as indicated. **f.** Clusters, with percentages of cells from each
682 health condition coloured as indicated. Dots represent a single cell (a-c).

683

684 **Supplementary Figure 2. Class-I related genes expression within the different B cell**
685 **clusters.** Heatmap representing scaled expression values of genes associated with antigen
686 uptake, processing and class-I presentation in each cluster.

687

688 **Supplementary Figure 3. Classical age-associated B cells upregulate AIRE in different**
689 **health conditions. a.** UMAP of total B cells showing AIRE+ cells coloured by density of
690 expression. **b.** UMAPs of total B cells per health condition coloured by kernel density
691 estimation of AIRE expression level (HC, healthy controls; ICB, immune-checkpoint
692 blockade treated patients; IEI CTLA-4/NFKB1, immune errors of immunity, CTLA-4 and
693 NFKB1 mutants respectively; SLE, systemic lupus erythematosus patients).

694

695 **Supplementary Figure 4. Decline of the neutralisation capacity after second dose of**
696 **BNT162b2 vaccine. a.** Gating strategy to identify age-associated B cell (ABCs,
697 SingletsLiveCD3-CD19+CD21-CD11+) subset from total B cell population (CD19+). **b.** IgG
698 end-point titres specific to the spike (S), receptor-binding domain (RBD) and nucleocapsid
699 (NCP) proteins of SARS-CoV2 at day 21 after the second dose of BNT162b2 vaccine. **c.**
700 Neutralising antibody titres at 50% inhibition (NT₅₀) against wildtype SARS-CoV-2 at
701 indicated timepoints after 2nd dose of BNT162b2 vaccine (healthy controls (HC), grey;
702 patients with rare inborn errors of immunity (IEI): (NFKB1) red, (CTLA-4 and unclassified)
703 orange; patients treated with ICB, blue). The limit of detection of the assays is shown (grey

704 dotted line at $NT_{50} = 20$). Where specified, statistical significance between groups was
705 determined using 2-way ANOVA with Tukey's multiple comparisons test.

706 **Supplementary Figure 5. Accumulation of age-associated B cells impairs humoral**
707 **responses to COVID-19 vaccination. a.** Gating strategy to identify RBD-specific B cell
708 (SingletsLiveStreptavidinBV711-CD19+RBDAF488+RBDAF647+) subset after the second
709 dose of BNT162b2 vaccine. **b.** Two-way ANOVA with Tukey's multiple comparisons test for
710 statistical analysis of RBD-binding B cells amongst groups. P values are indicated. **c.**
711 Multiple variable dot plots showing Spearman correlations between RBD-specific B cells and
712 NT_{50} at days 8, 21 and 105 after the second dose of BNT162b2 vaccine. Dot size represents
713 ABC frequency per individual. **d.** Correlation matrix using Spearman's rank correlation
714 amongst ABC and B cell frequencies at day 0; and RBD frequencies and NT_{50} values at
715 days 0, 8, 21 and 105 for the second dose of BNT162b2 vaccine. Data include all samples
716 enrolled in the study; Rho values are shown per correlation.

717

718 **Supplementary Table 1 – Differentially expressed genes related to Figure 1e**

719 **Supplementary Table 2 – Top 20 biological processes from the gene ontology**
720 **enrichment analysis**

721 **Supplementary Table 3 – Differentially expressed genes related to Figure 2a**

722 **Supplementary Table 4 – Characteristics of Inborn Errors of Immunity (IEI) patients**
723 **and Immune Checkpoint blockade treated (ICB) patients**

724 **Supplementary Table 5 – Flow cytometry antibodies details**

725

726 **Acknowledgements**

727 This work was funded by the MRC (grant ref. MC_UU_00025/12), the Medical Research
728 Foundation (MRF-057-0002-RG-THAV-C0798) and The Evelyn Trust (grant number 20/40).
729 NM was supported by the MRC (CSF ref. MR/P008801/1 to NJM), NHSBT (grant ref.
730 WPA15-02 to NJM) and Addenbrooke's Charitable Trust (grant ref. 900239 to NJM). The
731 authors thank the Flow Cytometry Services provided by Lucia Pereira Giraldez at the MRC-
732 Toxicology Unit, University of Cambridge and Katarzyna Kania from CRUK-CI-Genomics for
733 advice on single cell RNA sequencing experiments.

734

735 **Competing interest**

736 The authors declare no competing financial interests.

737

738 **Corresponding Authors**

739 Correspondence and requests for materials should be addressed to James Thaventhiran
740 (jedt2@cam.ac.uk) and Juan Carlos Yam-Puc (jcy28@cam.ac.uk).
741

742 **CITIID-NIHR BioResource COVID-19 Collaboration**

743 Stephen Baker^{2,6}, John Bradley^{1,3,6,11,15}, Patrick Chinnery^{3,23,24}, Daniel Cooper^{11, 25},
744 Gordon Dougan^{2,6}, Ian Goodfellow⁷, Ravindra Gupta^{2,6,13,16}, Nathalie Kingston^{3,4}, Paul J.
745 Lehner^{2,6,13}, Paul A. Lyons^{2,6}, Nicholas J. Matheson^{2,6,13,33}, Caroline Saunders⁹, Kenneth G.
746 C. Smith^{2,6}, Charlotte Summers^{6,12,26}, James Thaventhiran¹⁹, M. Estee Torok^{6,13,14}, Mark R.
747 Toshner^{6,8,26}, Michael P. Weekes^{2,6,13,34}, Gisele Alvio⁹, Sharon Baker⁹, Areti Bermpieri⁹, Karen
748 Brookes⁹, Ashlea Bucke, Jo Calder, Laura Canna, Cherry Crucusio, Isabel Cruz⁹, Ranalie de
749 Jesus⁹, Katie Dempsey⁹, Giovanni Di Stephano⁹, Jason Domingo⁹, Anne Elmer⁹, Julie
750 Harris, Sarah Hewitt, Heather Jones⁹, Sherly Jose⁹, Jane Kennet, Yvonne King, , Jenny
751 Kourampa⁹, Emily Li, Caroline McMahon⁹, Anne Meadows, Vivien Mendoza⁹, Criona
752 O'Brien, Charmain Ocaya⁹, Ciro Pasquale⁹, Marlyn Perales⁹, Jane Price, Rebecca Rastall,
753 Carla Ribeiro⁹, Jane Rowlands, Valentina Ruffolo, Hugo Tordesillas, Phoebe Vargas⁹, Bensi
754 Vergese⁹, Laura Watson⁹, Jieniean Worsley⁹, Julie-Ann Zerrudo⁹, Laura Bergamashi^{2,6},
755 Ariana Betancourt, Georgie Bower, Ben Bullman, Chiara Cossetti, Aloka De Sa, Benjamin J.
756 Dunmore, Maddie Epping, Stuart Fawke, Stefan Gräf^{3,6}, Richard Grenfell, Andrew Hinch,
757 Josh Hodgson, Christopher Huang, Oisín Huhn, Kelvin Hunter^{2,6}, Isobel Jarvis, Emma
758 Jones, Maša Josipović, Ekaterina Legchenko, Daniel Lewis, Joe Marsden, Jennifer Martin,
759 Federica Mescia^{2,6}, Ciara O'Donnell, Ommar Omarjee, Marianne Perera, Linda Pointon,
760 Nicole Pond, Nathan Richoz, Nika Romashova, Natalia Savoinykh, Rahul Sharma, Joy Shih,
761 Mateusz Strezlecki, Rachel Sutcliffe, Tobias Tilly, Zhen Tong, Carmen Treacy, Lori Turner,
762 Jennifer Wood, Marta Wylot, John Allison^{3,4}, Heather Biggs^{3,18}, John R. Bradley^{1,3,6,11,15},
763 Helen Butcher^{3,5}, Daniela Caputo^{3,5}, Matt Chandler^{3,5}, Patrick Chinnery^{3,23,24}, Debbie
764 Clapham-Riley^{3,5}, Eleanor Dewhurst^{3,5}, Christian Fernandez^{3,4}, Anita Furlong^{3,5}, Barbara
765 Graves^{3,5}, Jennifer Gray^{3,5}, Sabine Hein^{3,5}, Tasmin Ivers^{3,5}, Emma Le Gresley^{3,5}, Rachel
766 Linger^{3,5}, Mary Kasanicki^{3,11}, Rebecca King^{3,5}, Nathalie Kingston^{3,4}, Sarah Meloy^{3,5}, Alexei
767 Moulton^{3,5}, Francesca Muldoon^{3,5}, Nigel Ovington^{3,4}, Sofia Papadia^{3,5}, Christopher J.
768 Penkett^{3,4}, Isabel Phelan^{3,5}, Venkatesh Ranganath^{3,4}, Roxana Paraschiv^{3,4}, Abigail Sage^{3,5},
769 Jennifer Sambrook^{3,4}, Ingrid Scholtes^{3,5}, Katherine Schon^{3,17,18}, Hannah Stark^{3,5}, Kathleen E.
770 Stirrups^{3,4}, Paul Townsend^{3,4}, Neil Walker^{3,4}, Jennifer Webster^{3,5}, Mayurun Selvan³⁵, Petra,
771 Polgarova¹², Sarah L. Caddy^{2,6}, Laura G. Caller^{20,21}, Yasmin Chaudhry⁷, Martin D. Curran²²,
772 Theresa Feltwell⁶, Stewart Fuller²⁰, Iliana Georgana⁷, Grant Hall⁷, William L. Hamilton^{6,13,14},
773 Myra Hosmillo⁷, Charlotte J. Houldcroft⁶, Rhys Izuagbe⁷, Aminu S. Jahun⁷, Fahad A.
774 Khokhar^{2,6}, Anna G. Kovalenko⁷, Luke W. Meredith⁷, Surendra Parmar²², Malte L. Pinckert⁷,
775 Anna Yakovleva⁷, Emily C. Horner¹⁹, Lucy Booth¹⁹, Alexander Ferreira¹⁹, Rebecca Boston¹⁹,
776 Robert Hughes¹⁹, Juan Carlos Yam Puc¹⁹, Nonantzin Beristain-Covarrubias¹⁹, Maria Rust¹⁹,

777 Thevinya Gurugama¹⁹, Lihinya Gurugama¹⁹, Thomas Mulroney¹⁹, Sarah Spencer¹⁹, Zhaleh
778 Hosseini¹⁹, Kate Williamson¹⁹.

779

780 ¹NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus,
781 Cambridge, UK

782 ²Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey
783 Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK

784 ³NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge
785 Biomedical Campus, Cambridge, UK

786 ⁴Department of Haematology, School of Clinical Medicine, University of Cambridge,
787 Cambridge Biomedical Campus, Cambridge, UK

788 ⁵Department of Public Health and Primary Care, School of Clinical Medicine, University of
789 Cambridge, Cambridge Biomedical Campus, Cambridge, UK

790 ⁶Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge
791 Biomedical Campus, Cambridge, UK

792 ⁷Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK

793 ⁸Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK

794 ⁹Cambridge Clinical Research Centre, Addenbrooke's Hospital, Cambridge University
795 Hospitals NHS Foundation Trust, Cambridge, UK

796 ¹⁰Intensive Care Unit, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK

797 ¹¹Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust,
798 Cambridge Biomedical Campus, Cambridge, UK

799 ¹²Intensive Care Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS
800 Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK

801 ¹³Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge University NHS
802 Hospitals Foundation Trust, Cambridge, UK

803 ¹⁴Department of Microbiology, Addenbrooke's Hospital, Cambridge University NHS Hospitals
804 Foundation Trust, Cambridge, UK

805 ¹⁵Department of Renal Medicine, Addenbrooke's Hospital, Cambridge University Hospitals
806 NHS Foundation Trust, Cambridge, UK

807 ¹⁶Africa Health Research Institute, Durban, South Africa

808 ¹⁷Clinical Genetics, Addenbrooke's Hospital, Cambridge University Hospitals NHS
809 Foundation Trust, Cambridge, UK

810 ¹⁸Department of Clinical Neurosciences, School of Clinical Medicine, University of
811 Cambridge, Cambridge Biomedical Campus, Cambridge, UK

812 ¹⁹MRC Toxicology Unit, Gleeson Building, Tennis Court Road, Cambridge, UK

813 ²⁰University of Cambridge, Cambridge, UK
814 ²¹The Francis Crick Institute, London, UK
815 ²²Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, UK
816 ²³Department of Clinical Neurosciences, School of Clinical Medicine, University of
817 Cambridge, Cambridge Biomedical Campus, Cambridge, UK
818 ²⁴Medical Research Council Mitochondrial Biology Unit, Cambridge Biomedical Campus,
819 Cambridge, UK
820 ²⁵Global and Tropical Health Division, Menzies School of Heath Research and Charles
821 Darwin University, Darwin, Northern Territory, Australia
822 ²⁶Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge, UK
823 ²⁷Department of Rheumatology, Addenbrooke's Hospital, Cambridge University Hospitals
824 NHS Foundation Trust, Cambridge, UK
825 ²⁸Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge University Hospitals
826 NHS Foundation Trust, Cambridge, UK
827 ²⁹Department of Paediatrics, University of Cambridge, Cambridge Biomedical Campus,
828 Cambridge, UK
829 ³⁰Patient Safety, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation
830 Trust, Cambridge, UK
831 ³¹Clinical Research Network: Eastern, Addenbrooke's Hospital, Cambridge University
832 Hospitals NHS Foundation Trust, Cambridge, UK
833 ³²Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge University Hospitals
834 NHS Foundation Trust, Cambridge, UK
835 ³³NHS Blood and Transplant, Cambridge, UK
836 ³⁴Cambridge Institute for Medical Research, Biomedical Campus, Hills Rd, Cambridge UK
837 ³⁵ Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation
838 Trust, Cambridge, UK
839
840

841 **Method references**

842

843 1. Zheng, G.X., et al., Massively parallel digital transcriptional profiling of single cells.
844 Nat Commun, 2017. 8: p. 14049.

845 2. Roelli, P., B. Flynn, and G. Gui, Hoohm/CITE-seq-Count: 1.5.0. . Zenodo, 2019.

846 3. Hao, Y., et al., Integrated analysis of multimodal single-cell data. Cell, 2021. 184(13):
847 p. 3573-3587 e29.

848 4. McCarthy, D.J., et al., Scater: pre-processing, quality control, normalization and
849 visualization of single-cell RNA-seq data in R. Bioinformatics, 2017. 33(8): p. 1179-1186.

850 5. Bhamidipati, K., et al., CD52 Is Elevated on B cells of SLE Patients and Regulates B
851 Cell Function. Front Immunol, 2020. 11: p. 626820.

852 6. Ashburner, M., et al., Gene ontology: tool for the unification of biology. The Gene
853 Ontology Consortium. Nat Genet, 2000. 25(1): p. 25-9.

854 7. Gene Ontology, C., The Gene Ontology resource: enriching a GOld mine. Nucleic
855 Acids Res, 2021. 49(D1): p. D325-D334.

856 8. Mi, H., et al., PANTHER version 14: more genomes, a new PANTHER GO-slim and
857 improvements in enrichment analysis tools. Nucleic Acids Res, 2019. 47(D1): p. D419-D426.

858 9. Yamano, T., et al., Thymic B Cells Are Licensed to Present Self Antigens for Central
859 T Cell Tolerance Induction. Immunity, 2015. 42(6): p. 1048-61.

860 10. Alquicira-Hernandez, J. and J.E. Powell, Nebulosa recovers single cell gene
861 expression signals by kernel density estimation. Bioinformatics, 2021.

862 11. Xiong, X., et al., A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct
863 Mol Biol, 2020. 27(10): p. 934-941.

864 12. Collier, D.A., et al., Age-related immune response heterogeneity to SARS-CoV-2
865 vaccine BNT162b2. Nature, 2021. 596(7872): p. 417-422.

866 13. Stadlbauer, D., et al., SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol
867 for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol, 2020.
868 57(1): p. e100.


869 14. Daly, J.L., et al., Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science,
870 2020. 370(6518): p. 861-865.

871 15. Moore, S.C., et al., Amplicon-Based Detection and Sequencing of SARS-CoV-2 in
872 Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the
873 Viral Genome That Encode Proteins Involved in Interferon Antagonism. Viruses, 2020.
874 12(10).


875 16. Patterson, E.I., et al., Methods of Inactivation of SARS-CoV-2 for Downstream
876 Biological Assays. J Infect Dis, 2020. 222(9): p. 1462-1467.

- 877 17. Bergamaschi, L., et al., Longitudinal analysis reveals that delayed bystander CD8+ T
878 cell activation and early immune pathology distinguish severe COVID-19 from mild disease.
879 Immunity, 2021. 54(6): p. 1257-1275 e8.
- 880 18. Gerber, P.P., et al., A protease-activatable luminescent biosensor and reporter cell
881 line for authentic SARS-CoV-2 infection. PLoS Pathog, 2022. 18(2): p. e1010265.
- 882 19. Knezevic, I., et al., WHO International Standard for evaluation of the antibody
883 response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet
884 Microbe, 2022. 3(3): p. e235-e240.
- 885 20. Hedhammar, M. and S. Hober, Z(basic)--a novel purification tag for efficient protein
886 recovery. J Chromatogr A, 2007. 1161(1-2): p. 22-8.
- 887

Figure 1



Supplementary Figure 1



Supplementary Figure 2








Figure 2



Supplementary Figure 3







Figure 3




Supplementary Figure 4

a



b



c





Figure 4



Supplementary Figure 5

